EXCLUSIVE: Supplement Company Cymbiotika Opens First Wellness Café at Fontainebleau Las Vegas
The supplement company, best known for its liposomal packets, is opening its first Cymbiotika Wellness Café at the Fontainebleau's food hall Promenade later this summer. At the café, guests will be able to experience smoothies, juices, açai bowls, yogurt bowls, salads and wraps featuring the brand's supplements. By adding Cymbiotika products to these beverages and meals, guests can opt for a specific health goal, from boosting immunity to supporting focus. There will also be grab-and-go items, as well as Cymbiotika products available.
More from WWD
How Rising Temperatures Are Raising the Bar for Beauty and Wellness
EXCLUSIVE: Nara Smith Fronts Vegamour Hair Supplement Campaign
EXCLUSIVE: Kourtney Kardashian Barker's Lemme Is Launching a Greens Gummy Filled With 20 Fruits and Vegetables
Some of the brand's bestselling products include Liposomal Vitamin C, $62, and Liposomal Glutathione, $88, and new launches include Liquid Colostrum, $88, and Irish Sea Moss, $65.
'Opening our inaugural Cymbiotika Wellness Café at such an iconic and forward-thinking destination like Fontainebleau Las Vegas is a monumental achievement for us,' said Cymbiotika cofounder and chief executive officer Shahab Elmi in a statement. 'Our mission has always been to empower individuals on their wellness journeys, and this café provides a unique way to experience the benefits of our supplements in a convenient and delicious format. We are excited to be part of Fontainebleau Las Vegas' continued commitment to guest well-being.'
While the words Vegas and wellness may seem like polar opposites, the party destination has been getting a bit of a health refresh. For example, in-room IV drips, juice bars and luxe gyms have become the norm along the Strip.
'People aren't really drinking anymore. Vegas once was an absolute party scene, and still is, but I think now… the environment is changing. Everything is about health and supplementation and finding alternatives to drinking but still having a good time,' said cofounder and chief operating officer Durana Elmi. 'Generations now are so much more health-conscious and so much smarter in terms of how they're living their life. They're still having a good time. They're still partying… but they're doing it in a way where they're not damaging their body.'
Fountainebleau, in particular, has a NutriDrip IV Lounge, IGK Salon, luxury fitness center and its Lapis Spa and Wellness.
In a statement, Michael Waltman, senior vice president of hospitality and nightlife at Fontainebleau, added: 'Health and wellness have always been key pillars of the Fontainebleau Las Vegas guest experience. From the award-winning Lapis Spa & Wellness to our innovative fitness center, we pride ourselves on being a leader in wellness tourism with our best-in-class amenities and offerings. This partnership with Cymbiotika brings a natural synergy across our culinary, spa and fitness offerings, furthering our commitment to delivering a holistic and enriching stay at every touchpoint.'
The Cymbiotika Wellness Café is expected to open late summer.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Vera Whole Health and Castlight Health Join Forces with Aligned Marketplace to Expand High-Quality Care Solutions
Strategic partnership expands access to advanced primary care for self-insured employers and unlocks integrated navigation nationwide SEATTLE and NEW YORK, Aug. 21, 2025 /PRNewswire/ -- Aligned Marketplace, an advanced primary care marketplace for self-insured employers, is entering into a strategic partnership with Vera Whole Health and Castlight Health to offer solutions that will connect more members to accessible, affordable and comprehensive primary care. Employers now have access to Vera Whole Health's network of advanced primary care centers and virtual care through Aligned Marketplace. In parallel, Aligned Marketplace has joined the Castlight Ecosystem, enabling employers to purchase an integrated solution that connects navigation with high-performing care delivery. "Aligned Marketplace is redefining how self-insured employers purchase primary care – offering an innovative solution with nationwide reach," said Victor Leclere, senior vice president of Growth and Partnerships for apree health, the parent company of Vera Whole Health and Castlight Health. "Our partnership further expands access to high-quality primary care for Aligned's employers and embeds navigation directly into Aligned's network, connecting the experience from point of need to point of care, driving higher engagement and better outcomes." Vera Whole Health will launch in the Aligned Marketplace during the third quarter of 2025, beginning with select markets including Alaska, Connecticut, Georgia, Nevada, Oregon and Washington. Additional markets will be phased in over time, creating a comprehensive nationwide footprint for participating employers. With Aligned Marketplace available in the Castlight Ecosystem by next quarter, employers will have the opportunity to offer more robust experience. Castlight provides an easy-to-use platform through which members can receive curated health navigation that helps them understand their benefits and access the right care at the right time by connecting members with coordinated care teams – including primary care providers, behavioral health specialists and health coaches. "Our mission at Aligned Marketplace is to increase America's healthspan by bringing personalized primary care to America's workforce, and we do that by connecting employers with our national marketplace of advanced primary care providers," said Patrick Nelli, founder and CEO of Aligned Marketplace. "By partnering with Castlight, we're making it easier for members to understand, access and act on their care. By streamlining how they navigate benefits and boosting engagement, we're helping employers drive down healthcare costs and improve member outcomes." About Aligned MarketplaceAligned Marketplace is an advanced primary care marketplace for self-insured employers. Aligned is an easy and effective way to give employees access to advanced primary care – care that is designed to keep them healthy and proven to reduce health care costs by as much as 15%. With a single value-based, shared savings contract, employers see a return on investing in their employees' improved health. By integrating seamlessly into existing health plans, Aligned Marketplace takes the pain and complexity out of offering advanced primary care. Founded in 2023 by an experienced team of health care veterans, Aligned Marketplace's network includes more than 3,000 advanced primary care clinics in all 50 states. For more information, go to About apree healthapree health brings together Castlight Health and Vera Whole Health, combining clinical advocacy and navigation with advanced primary care delivery. With this approach, apree can better understand individuals' health risks, challenges and goals; engage them with personalized outreach and recommendations; and manage their care by providing an integrated and coordinated care experience. This unique model helps patients achieve better health, lowers the total cost of care and improves the experience for individuals, employers and health plans. For more information, visit About Castlight HealthCastlight Health simplifies healthcare navigation by providing a comprehensive and highly tailored digital platform and clinical services. Leveraging advanced personalization capabilities, Castlight identifies individual needs to deliver customized health and wellbeing experiences, guiding individuals through their unique health journeys and helping them engage with the right programs and care at the right time. Founded in 2008, Castlight enables large employers and health plans to drive better outcomes, improve engagement and maximize the value of healthcare benefits. For more information, visit About Vera Whole HealthFounded in 2008, Vera Whole Health is leading the shift to value-based care using an advanced primary care model that delivers a superior experience, providing longer appointments, same or next-day access, and both in-person and virtual care. By integrating data-driven insights and multifunctional care teams, Vera improves health outcomes, reduces total cost of care and consistently achieves a best-in-class member experience. Vera currently owns and operates care centers in 11 states across the U.S. In 2022, Vera merged with Castlight to create apree health family of brands. In 2024, apree health became a business unit of Mosaic Health. For more information, visit About Mosaic HealthMosaic Health is a national care delivery platform focused on expanding access to comprehensive primary care for consumers with coverage across Commercial, Individual Exchange, Medicare and Medicaid health plans. The Business Units which comprise Mosaic Health, including apree health, Millennium Physician Group and CareMore Health, are multi-payer and serve nearly one million consumers across 19 states, providing them with access to high-quality primary care, integrated care teams, personalized navigation, expanded digital access and specialized services for higher-need populations. Through Mosaic Health, health plans and employers have an even stronger care provider partner that delivers affordability and superior experiences for their members and employees, including value-based primary care capacity integrated with digital patient engagement and navigation. Each of the companies within Mosaic Health provide unique offerings that together promise to improve individuals' health and wellbeing, while helping care providers deliver higher-quality care. For more information, please visit or follow Mosaic Health on LinkedIn. Media ContactsErin Bocherer, for apree health678-294-2258erin@ Dori Zweig Young, for Aligned MarketplaceAligned@ View original content to download multimedia: SOURCE Castlight Health, Inc. Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
From Pain Point to Game Changer: Welove Creations Wins 2025 Red Dot Design Award, Setting a New Standard for the Future of Hearing Protection
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Welove Creations proudly announces that its innovative Welove Earplugs have won the prestigious Red Dot Design Award 2025, affirming its place among the world's leading hearing protection solutions. 'A harmonious combination of comfortable fit, sophisticated functionality, and attractive design. The practical UV-sanitizing case is another impressive detail.' The remarkable quality and design won over the international Red Dot Jury. Ergonomically crafted to redefine earplug comfort, Welove Earplugs are the world's first to combine a design that mirrors the contours of the ear with a UV-sanitizing case, featuring SGS-certified 18 dB NRR noise reduction — a breakthrough in hearing safety. The design offers a virtually weightless feel with effective noise cancelling, ensuring safe, secure, and hygienic comfort for long-term wear — ideal for restful sleep, deep focus, stress-free travel, and all-day comfort. Recognized as the best earplugs for sleeping, Welove Earplugs address long-standing issues of discomfort, poor fit, and hygiene — challenges that have plagued users for years. This innovative solution is rapidly reshaping the hearing protection market, elevating earplugs from disposable items to daily essentials. Trusted by sleep experts, healthcare professionals, musicians, travelers, and even former Olympians, Welove Earplugs are now showcased at the Red Dot Design Museum in Essen, Germany, which attracts over 150,000 design enthusiasts each year, joining the ranks of globally recognized icons of innovation. The craftsmanship behind the award: after more than a decade of tinnitus and noise sensitivity, the founder struggled to find earplugs she could wear comfortably day and night. She assembled a three-person team and, over 450 days of relentless refinement, created the industry's most comfortable earplugs for prolonged wear, instantly ranking among the world's finest upon launch. "Peace begins with care, and love drives everything we do," says the Welove team. "This award further reinforces our mission to craft high-quality products that inspire joy and connection, helping people live life to the fullest. Our dove logo embodies this belief: in a chaotic world, find peace in love.' With growing global recognition, Welove Creations remains committed to dedication, expertise, and sincerity — proving that with love and the courage to innovate, even a small team can set new standards on the world stage. About us: hello@ A photo accompanying this announcement is available at
Yahoo
8 minutes ago
- Yahoo
The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know
Key Points Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline. The company looks attractively valued following its underperformance over the past 12 months. 10 stocks we like better than Novo Nordisk › The past 12 months haven't been great for Novo Nordisk (NYSE: NVO). Its shares peaked last year and have been in a downward spiral due to unimpressive financial results, clinical setbacks, and mounting competition in its core areas of expertise. However, Novo Nordisk is looking to bounce back. Recent regulatory progress could be a positive step in that direction. Here's what investors need to know. Another important approval On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why. MASH is a disease characterized by the accumulation of fat in the liver, leading to inflammation. According to some estimates, 22 million adults in the U.S. have MASH, although fewer, about 9 million, have clinically meaningful liver disease. That's not an insignificant number, and one might think that, given this large addressable market, there are many approved therapies for MASH. But that's not the case. Developing effective treatments has proven to be surprisingly challenging. Last year, the FDA approved the first therapy specifically for MASH. Now, Wegovy has become the first GLP-1 medicine to earn that indication. Although there are other treatments in development, Wegovy could carve out a decent market for itself in MASH, especially since it posted phase 3 results comparable to those of its only competitor on the market (for now): Rezdiffra, marketed by Madrigal Pharmaceuticals. Novo Nordisk is a significantly larger company with more funds, a larger marketing budget, and a larger sales team than its smaller peer. What will be the demand for Wegovy in MASH be? We can gather some clues from Rezdiffra's launch, which is going extremely well. About a year after it hit the market, Rezdiffra generated $212.8 million in revenue in the second quarter -- that's impressive and points to a massive demand for the medicine. Yet, Madrigal has barely scratched the surface of the addressable market. As of June 30, it had treated just over 23,000 patients. Wegovy's launch in MASH should be even smoother since it isn't starting from scratch -- it's already been on the market for several years. In my view, this new indication could add over $1 billion in sales to Wegovy's total within the next few years, especially because it's also being considered for approval for MASH in Japan and the European Union. It's also worth pointing out another development that helped jolt Novo Nordisk's stock price. The company is partnering with GoodRx to offer Ozempic at a reduced cost for patients who pay out of pocket. This move should help it deal with some companies that sell compounded versions of Ozempic for less. Is Novo Nordisk's stock a buy? Wegovy could earn yet another important label expansion by next year, although in a different version. Earlier this year, Novo Nordisk requested approval for an oral formulation of the medicine for weight loss. That could also move the needle for the pharmaceutical giant. An oral version would be faster and cheaper to produce, easier to transport, and thus more cost-effective to manufacture at scale. The previous shortages Wegovy dealt with would be far less likely to occur with an oral formulation. Notably, it would mark yet another breakthrough for Novo Nordisk. There is currently no oral GLP-1 medication approved for weight loss -- the drugmaker's own Rybelsus, an oral GLP-1 product, is indicated only for diabetes. Meanwhile, Novo Nordisk's financial results remain strong. In the first half of the year, net sales grew by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit of 55.5 billion DKK ($8.7 billion) rose 22% compared to the year-ago period. Furthermore, Novo Nordisk has an attractive pipeline. CagriSema, a next-generation GLP-1 therapy whose phase 3 results were strong (if not as strong as the market had hoped), appears poised to become a blockbuster. Some analysts predict that it will generate $15.2 billion in revenue by 2030. Elsewhere, Novo Nordisk's amycretin, another investigational weight loss therapy, recently started phase 3 studies in both oral and subcutaneous formulations. Despite recent clinical setbacks, Novo Nordisk's pipeline should earn some significant wins in the next few years, particularly since the company has been strengthening it through licensing deals. Lastly, Novo Nordisk stock looks reasonably valued. The company is trading at 13.5 times forward earnings, compared to an average price-to-earnings ratio of 16.5 for the healthcare industry. At current levels, the stock could deliver superior returns to investors who initiate positions today. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,052% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
